Beam Therapeutics Inc (NAS:BEAM)
$ 23.53 -0.83 (-3.41%) Market Cap: 1.94 Bil Enterprise Value: 1.16 Bil PE Ratio: 0 PB Ratio: 2.27 GF Score: 54/100

Beam Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 07, 2022 / 07:55PM GMT
Release Date Price: $44.1 (+2.13%)
Operator

Ladies and gentlemen, the program is about to begin. Reminder that you can submit questions at any time via the ask questions tab on the webcast page.

At this time, it is my pleasure to turn the program over to your host, Greg Harrison.

Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Hi, and welcome to the Bank of America SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analyst here at BofA. And today, I'm happy to introduce Beam Therapeutics, represented by John Evans, CEO; and Giuseppe Ciaramella, President and Chief Scientific Officer. Thanks for joining us, everyone. And for those of you out there watching, if you want to send any questions, I'm happy to ask them on your behalf.

John, if you'd like to start off with some opening remarks, that would be great, and then we can jump into Q&A.

John M. Evans
Beam Therapeutics Inc. - CEO & Director

Sounds good. It's great to be here, Greg, and thanks for having us. So Beam, as people may be familiar

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot